New From CFR: Thomas Bollyky on Drug Patents in the Developing World
A man buys the cancer drug Glivec for a relative who is suffering from cancer at a pharmacy in a government-run hospital in the western Indian city of Ahmedabad on April 2, 2013 (Amit Dave/Courtesy Reuters).
In light of an Indian court’s refusal to grant a patent to the leukemia drug Gleevec, CFR senior fellow Thomas Bollyky wrote yesterday about the tension between pharmaceutical firms seeking compensation for their products and developing countries seeking to make drugs more affordable to their populations. As he argues: Read more »



